Late-Onset Asthma: A Review
Downloads
Asthma is a chronic respiratory condition with a growing global prevalence, affecting millions of individuals annually. While asthma can develop at any age, late-onset asthma is a specific phenotype that begins in adulthood, as recognized by the Global Initiative for Asthma (GINA) in its 2024 guidelines. This form of asthma is often associated with several predisposing factors, including gender, obesity, occupational exposure, rhinitis, respiratory infections, smoking, stress, and diminished lung function. Unlike early-onset asthma, which frequently involves a history of allergies, late-onset asthma tends to lack allergic triggers, making it a distinct and challenging form of the disease. Managing late-onset asthma is often more complex, as it typically requires higher doses of corticosteroids and demonstrates a reduced responsiveness to standard steroid treatments. The exact mechanisms and pathophysiological processes contributing to the increased severity and poorer clinical outcomes in late-onset asthma remain largely unclear. This uncertainty often leads to underdiagnosis and inadequate management, further complicating patient care. Phenotypic analysis is recommended to improve treatment outcomes. This includes assessing clinical features and utilizing biomarkers, such as inflammatory markers and immunoglobulin E (IgE) levels, to guide targeted therapy when conventional steroid treatments are insufficient. However, there is a significant need for further research to elucidate the underlying mechanisms of late-onset asthma. This literature review is essential to develop more effective, personalized treatment strategies that can address the unique challenges posed by this asthma phenotype, ultimately leading to better management and improved patient outcomes.
Global Initiative for Asthma (GINA). Global Strategy for Asthma Management and Prevention. Wisconsin, https://ginasthma.org/wp-content/uploads/2024/05/GINA-2024-Strategy-Report-24_05_22_WMS.pdf (2024).
GBD 2019 Stroke Collaborators. Global, Regional, and National Burden of Stroke and Its Risk Factors, 1990-2019: A Systematic Analysis for the Global Burden of Disease Study 2019. Lancet Neurol 2021; 20: 795–820. [PubMed]
Kementerian Kesehatan Republik Indonesia. Hasil Utama RISKESDAS 2018. Jakarta, https://kesmas.kemkes.go.id/assets/upload/dir_519d41d8cd98f00/files/Hasil-riskesdas-2018_1274.pdf (2018).
Badan Pusat Statistik. Profil Statistik Kesehatan 2021. Jakarta, https://www.bps.go.id/id/publication/2021/12/22/0f207323902633342a1f6b01/profil-statistik-kesehatan-2021.html (2021).
Perhimpunan Dokter Paru Indonesia (PDPI). Pedoman Diagnosis dan Penatalaksanaan di Indonesia. Jakarta, 2021.
Hirano T, Matsunaga K. Late-Onset Asthma: Current Perspectives. J Asthma Allergy 2018; 11: 19–27. [PubMed]
Aarab R, Vijverberg SJH, Prins M, et al. Prevalence of and Factors Associated with Adult-Onset Asthma in Different Ethnic Groups: The HELIUS Study. Respir Med 2019; 150: 113–119. [PubMed]
Ilmarinen P, Tuomisto LE, Kankaanranta H. Phenotypes, Risk Factors, and Mechanisms of Adult-Onset Asthma. Mediators Inflamm 2015; 2015: 514868. [PubMed]
Wu TJ, Chen BY, Lee YL, et al. Different Severity and Severity Predictors in Early-Onset and Late-Onset Asthma: A Taiwanese Population-Based Study. Respiration 2015; 90: 384–392. [PubMed]
Song WJ, Kang MG, Chang YS, et al. Epidemiology of Adult Asthma in Asia: Toward a Better Understanding. Asia Pac Allergy 2014; 4: 75–85. [PubMed]
Quirce S, Heffler E, Nenasheva N, et al. Revisiting Late-Onset Asthma: Clinical Characteristics and Association with Allergy. J Asthma Allergy 2020; 13: 743–752. [PubMed]
Peebles RSJ, Aronica MA. Proinflammatory Pathways in the Pathogenesis of Asthma. Clin Chest Med 2019; 40: 29–50. [PubMed]
Amelink M, de Nijs SB, de Groot JC, et al. Three Phenotypes of Adult-Onset Asthma. Allergy 2013; 68: 674–680. [PubMed]
Abreu SC, Antunes MA, Xisto DG, et al. Bone Marrow, Adipose, and Lung Tissue-Derived Murine Mesenchymal Stromal Cells Release Different Mediators and Differentially Affect Airway and Lung Parenchyma in Experimental Asthma. Stem Cells Transl Med 2017; 6: 1557–1567. [PubMed]
de Nijs SB, Venekamp LN, Bel EH. Adult-Onset Asthma: Is It Really Different? Eur Respir Rev 2013; 22: 44 LP – 52. [PubMed]
Song WJ, Chang YS, Lim MK, et al. Staphylococcal Enterotoxin Sensitization in a Community-Based Population: A Potential Role in Adult-Onset Asthma. Clin Exp Allergy 2014; 44: 553–562. [PubMed]
Iwata M, Ota KT, Duman RS. The Inflammasome: Pathways Linking Psychological Stress, Depression, and Systemic Illnesses. Brain Behav Immun 2013; 31: 105–114. [PubMed]
Choi S, Hoffman EA, Wenzel SE, et al. Quantitative Computed Tomographic Imaging-Based Clustering Differentiates Asthmatic Subgroups with Distinctive Clinical Phenotypes. J Allergy Clin Immunol 2017; 140: 690-700.e8. [PubMed]
Matsunaga K, Akamatsu K, Hirano T, et al. Response to Treatment in Individuals with Late-Onset Asthma. Journal of the American Geriatrics Society 2012; 60: 1587–1588. [PubMed]
Ulrik CS. Late-Onset Asthma: A Diagnostic and Management Challenge. Drugs Aging 2017; 34: 157–162. [PubMed]
Brusselle G, Germinaro M, Weiss S, et al. Reslizumab in Patients with Inadequately Controlled Late-Onset Asthma and Elevated Blood Eosinophils. Pulm Pharmacol Ther 2017; 43: 39–45. [PubMed]
Holgate S, Buhl R, Bousquet J, et al. The Use of Omalizumab in the Treatment of Severe Allergic Asthma: A Clinical Experience Update. Respir Med 2009; 103: 1098–1113. [PubMed]
Holguin F, Bleecker ER, Busse WW, et al. Obesity and Asthma: An Association Modified by Age of Asthma Onset. J Allergy Clin Immunol 2011; 127: 1486–93.e2. [PubMed]
Sze E, Bhalla A, Nair P. Mechanisms and Therapeutic Strategies for Non-T2 Asthma. Allergy 2020; 75: 311–325. [PubMed]
Hinks TSC, Levine SJ, Brusselle GG. Treatment Options in Type-2 Low Asthma. Eur Respir J; 57. Epub ahead of print January 2021. [PubMed]
Borish L. The Immunology of Asthma: Asthma Phenotypes and Their Implications for Personalized Treatment. Ann Allergy Asthma Immunol 2016; 117: 108–114. [PubMed]
Wu TJ, Wu CF, Chen BY, et al. Age of Asthma Onset and Vulnerability to Ambient Air Pollution: An Observational Population-Based Study of Adults from Southern Taiwan. BMC Pulm Med 2016; 16: 54. [PubMed]
Özyiğit LP, Öztürk AB, Bavbek S. Anti-IL-5 Biologicals Targeting Severe Late Onset Eosinophilic Asthma. Turkish Thorac J 2020; 21: 61–68. [PubMed]
Parnes JR, Molfino NA, Colice G, et al. Targeting TSLP in Asthma. J Asthma Allergy 2022; 15: 749–765. [PubMed]
Copyright (c) 2024 Yandi Noer Moelamsyah, Faisal Yunus, Fariz Nurwidya, Bagus Radityo Amien
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.
1. The journal allows the author to hold the copyright of the article without restrictions.
2. The journal allows the author(s) to retain publishing rights without restrictions.
3. The legal formal aspect of journal publication accessibility refers to Creative Commons Attribution Share-Alike (CC BY-SA).
4. The Creative Commons Attribution Share-Alike (CC BY-SA) license allows re-distribution and re-use of a licensed work on the conditions that the creator is appropriately credited and that any derivative work is made available under "the same, similar or a compatible license”. Other than the conditions mentioned above, the editorial board is not responsible for copyright violation.